Filing Flows › Assembly Biosciences (ASMB) › Q4 2024
Assembly Biosciences (ASMB) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 20, 2025
Assembly Biosciences (ASMB) reported revenue of $7.4M for the fourth quarter 2024 (Q4 2024), +3% from a year earlier and +7% from the quarter before. Operating margin was -156.7%, net loss $10.3M (140.5% of revenue).
Assembly Biosciences, Q4 2024: revenue $7.4M (+3% year over year), operating margin -156.7%, net loss $10.3M, operating cash flow −$407K. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $7.4M | +7% | +3% |
| Operating profit | −$11.5M | — | — |
| Net earnings | −$10.3M | — | — |
| Operating cash flow | −$407K | — | — |
What changed
Revenue was $7.4M in Q4 2024, up 3% year over year and up 7% from the previous quarter.
Operating costs exceeded revenue by $11.5M, an operating margin of -156.7%. Total costs fell 4% while revenue rose 3%. The fastest-growing cost line was Research & development (+30%). The quarter ended with a net loss of $10.3M, wider than the previous quarter's $9.6M loss.
Operating cash flow was −$407K. Non-cash charges added back $32K of depreciation and amortization and $751K of share-based compensation. Working capital and other items added $9.1M.
Questions
What was Assembly Biosciences' revenue in the fourth quarter 2024?
Assembly Biosciences (ASMB) reported revenue of $7.4M for the fourth quarter 2024 (Q4 2024), +3% from a year earlier and +7% from the quarter before.
Was Assembly Biosciences profitable in the fourth quarter 2024?
Operating loss was $11.5M (-156.7% of revenue) and net loss $10.3M.